Drug shortage
Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension · Novo Nordisk, Inc.
FDA drug shortage · To Be Discontinued · updated Jul 21, 2025
Key facts
| Generic name | Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension |
|---|---|
| Company | Novo Nordisk, Inc. |
| Presentation | Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11) |
| Dosage form | Injectable Suspension |
| Status | To Be Discontinued |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 73070-200-11 |
| First posted | Jul 21, 2025 |
| Last updated | Jul 21, 2025 |
| Discontinued | Jul 21, 2025 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: